{"organizations": [], "uuid": "5df5b6fafbd8fcb7b8934fdca504b31d2d81ce64", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biomarin-pharmaceutical-q1-gaap-lo/brief-biomarin-pharmaceutical-q1-gaap-loss-per-share-0-26-idUSL8N1S295I", "country": "US", "domain_rank": 408, "title": "BRIEF-Biomarin Pharmaceutical Q1 GAAP Loss Per Share $0.26", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T00:56:00.000+03:00", "replies_count": 0, "uuid": "5df5b6fafbd8fcb7b8934fdca504b31d2d81ce64"}, "author": "", "url": "https://www.reuters.com/article/brief-biomarin-pharmaceutical-q1-gaap-lo/brief-biomarin-pharmaceutical-q1-gaap-loss-per-share-0-26-idUSL8N1S295I", "ord_in_thread": 0, "title": "BRIEF-Biomarin Pharmaceutical Q1 GAAP Loss Per Share $0.26", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "biomarin", "sentiment": "none"}, {"name": "biomarin pharmaceutical inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Biomarin Pharmaceutical Inc:\n* BIOMARIN ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS * Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION\n* Q1 GAAP LOSS PER SHARE $0.26 * Q1 EARNINGS PER SHARE VIEW $-0.17 â€” THOMSON REUTERS I/B/E/S\n* SEES FY 2018 REVENUE ABOUT $1.5 BILLION * AS OF MARCH 31, 2018, BIOMARIN HAD CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALING ABOUT $1.7 BILLION Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-26T00:56:00.000+03:00", "crawled": "2018-04-26T01:04:31.001+03:00", "highlightTitle": ""}